Huntington's disease is a fatal inherited brain disorder caused by a genetic mutation that produces toxic huntingtin protein. About 30,000 people in the U.S. have the disease, which causes progressive movement, cognitive, and psychiatric problems. There is no treatment that slows or stops the disease.
What's actually going on in research
Active trials are testing huntingtin-lowering drugs that reduce the toxic protein, neuroprotective agents that may preserve brain cells, and treatments for chorea and other symptoms. Researchers are also studying when to start treatment, biomarkers that track disease progression, and gene therapy approaches that aim to silence the mutation at its source.
Huntingtin-lowering drugs
Several drugs work to reduce production of the toxic huntingtin protein. Some are delivered by monthly spinal injection, while newer approaches test pills and gene therapies that may work with less frequent dosing.
Symptom treatments
Trials are testing drugs for chorea (involuntary movements), irritability, apathy, and cognitive decline. Deutetrabenazine was FDA-approved in 2017 for chorea, and research continues on drugs that may address multiple symptoms.
Gene therapy
New gene-silencing approaches aim to turn off the mutated huntingtin gene with a single treatment. Early trials are testing whether these can provide lasting benefit without repeated dosing.
What to know before you search
Eligibility usually depends on genetic testing confirming the mutation, disease stage (early, middle, or late), functional capacity scores, and sometimes whether you have symptoms yet.
What types of trials are currently open
- Huntingtin-lowering trials — Testing drugs that reduce production of the toxic protein, often given by spinal injection monthly or by newer methods. These aim to slow disease progression.
- Neuroprotection trials — Testing drugs that may protect brain cells from damage, even if they don't lower huntingtin protein levels.
- Symptom trials — Testing treatments for chorea, irritability, depression, or cognitive problems. Some focus on single symptoms, others on multiple.
- Gene therapy trials — Testing one-time treatments that aim to silence the mutated gene. These use modified viruses or other methods to deliver genetic instructions.
- Natural history studies — Following people with the Huntington's gene to understand how the disease progresses and test biomarkers. These don't test treatments but help future trial design.
Recently added Huntington's Disease trials
Take a therapy being tested to slow Huntington's disease decline
The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.
Take a first-in-human gene therapy for Huntington's disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
Find Huntington's Disease trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.